REGN logo

REGN
Regeneron Pharmaceuticals, Inc.

17,549
Mkt Cap
$62.04B
Volume
2.12M
52W High
$935.86
52W Low
$476.49
PE Ratio
14.75
REGN Fundamentals
Price
$654.48
Prev Close
$585.31
Open
$612.02
50D MA
$576.41
Beta
0.59
Avg. Volume
1.08M
EPS (Annual)
$38.34
P/B
2.08
Rev/Employee
$940,156.23
Loading...
Loading...
News
all
press releases
REGN Stock Up on Q3 Earnings Beat, Eylea HD Sales Increase
Regeneron's Q3 earnings beat forecasts as strong Dupixent profits and rising Eylea HD sales offset a decline in its flagship Eylea brand.
Zacks·2h ago
News Placeholder
More News
News Placeholder
Compared to Estimates, Regeneron (REGN) Q3 Earnings: A Look at Key Metrics
Although the revenue and EPS for Regeneron (REGN) give a sense of how its business performed in the quarter ended September 2025, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Zacks·7h ago
News Placeholder
Regeneron (REGN) Q3 Earnings and Revenues Surpass Estimates
Regeneron (REGN) delivered earnings and revenue surprises of +25.32% and +4.38%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·9h ago
News Placeholder
Sanofi Q3 Earnings Beat, Dupixent Drives Growth as Vaccines Decline
Sanofi's Q3 earnings top forecasts as Dupixent surges past EUR 4B in sales, offsetting weakness in vaccines.
Zacks·4d ago
News Placeholder
REGN Q3 Earnings: Will Higher Dupixent Profits Offset Eylea Sales Decline?
Regeneron's Q3 earnings on Oct. 28 will likely spotlight Dupixent profits and strong Eylea HD uptake amid lingering Eylea competition.
Zacks·4d ago
News Placeholder
Exploring Analyst Estimates for Regeneron (REGN) Q3 Earnings, Beyond Revenue and EPS
Evaluate the expected performance of Regeneron (REGN) for the quarter ended September 2025, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of its key metrics for better insight.
Zacks·5d ago
News Placeholder
RHHBY's Sales Up 7% in First 9 Months of 2025, '25 Earnings View Raised
Roche's Q3 sales climbed 6% to CHF 14.9B, powered by surging demand for Phesgo, Xolair, Hemlibra, Vabysmo, and Ocrevus.
Zacks·5d ago
News Placeholder
Earnings Preview: Regeneron (REGN) Q3 Earnings Expected to Decline
Regeneron (REGN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Zacks·7d ago
News Placeholder
Can NTLA's In Vivo Pipeline Aid Long-Term Growth Amid Competition?
Intellia banks on its late-stage gene-editing therapies, lonvo-z and nex-z, that could define its long-term growth phase in the gene editing space.
Zacks·8d ago
News Placeholder
Revolution Medicines, Disc Medicine, Regeneron Stocks Jump After-Hours As FDA Fast-Tracks 9 Drugs Under New Review Program
The FDA’s new National Priority Voucher pilot helps with faster drug reviews, cutting timelines from nearly a year to weeks.
Stocktwits·12d ago

Latest REGN News

View

Advertisement|Remove ads.

Advertisement|Remove ads.